Company / EPS (Diluted)
aTYR PHARMA INC EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.94
FY2025
5-year range
-$7.03 / -$0.94
FY2021-FY2025
Trend
+41.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-1.77 to $-0.94 over the past 2 years.
Based on SEC 10-K filings.
-0.94 in FY2025.
Improved from $-1.77 to $-0.94 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 41.3% year-over-year.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.94 | +41.3% |
| FY2024 | -$1.60 | +9.6% |
| FY2023 | -$1.77 | +0.0% |
| FY2022 | -$1.77 | +74.8% |
| FY2021 | -$7.03 | +56.4% |
| FY2020 | -$16.11 | +38.3% |
| FY2019 | -$26.13 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026